LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

AstraZeneca PLC ADR

Uždarymo kaina

72.9 0.84

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

72.29

Max

73.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.7B

3.4B

Pardavimai

-1.3B

14B

P/E

Sektoriaus vid.

29.004

51.198

Pelnas, tenkantis vienai akcijai

0.934

Dividendų pajamingumas

2.15

Pelno marža

25.037

Darbuotojai

94,300

EBITDA

610M

5B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+20.44% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.15%

2.40%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

7.5B

224B

Ankstesnė atidarymo kaina

72.06

Ankstesnė uždarymo kaina

72.9

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

AstraZeneca PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-12 09:36; UTC

Pagrindinės rinkos jėgos

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

2025-04-29 10:14; UTC

Uždarbis

Correction to AstraZeneca Update

2025-04-29 09:15; UTC

Uždarbis

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

2025-04-29 08:12; UTC

Uždarbis

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

2025-04-29 06:32; UTC

Uždarbis

AstraZeneca Sales, Earnings Rise

2025-03-24 03:15; UTC

Pagrindinės rinkos jėgos

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New -2-

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

2025-05-20 06:09; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca Completes Acquisition of EsoBiotec

2025-05-12 12:07; UTC

Rinkos pokalbiai

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025-05-12 07:20; UTC

Rinkos pokalbiai

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

2025-05-08 15:20; UTC

Uždarbis

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

2025-04-29 13:09; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

2025-04-29 08:04; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

2025-04-29 06:05; UTC

Uždarbis

AstraZeneca 1Q Core EPS $2.49

2025-04-29 06:04; UTC

Uždarbis

AstraZeneca 1Q Net Pft $2.92B

2025-04-29 06:02; UTC

Uždarbis

AstraZeneca: Committed to Further Invest and Grow in the U.S.

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca 1Q Core EPS Consensus Was $2.27

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca 1Q Revenue Consensus Was $13.80B

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca Backs 2025 View

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q EPS $1.87

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Rev $13.59B

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Oper Pft $3.67B

2025-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Pretax Pft $3.4B

2025-04-15 09:55; UTC

Rinkos pokalbiai

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2025-04-09 07:23; UTC

Rinkos pokalbiai

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

2025-04-03 08:41; UTC

Rinkos pokalbiai

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

2025-04-03 08:36; UTC

Rinkos pokalbiai

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

2025-04-03 07:51; UTC

Rinkos pokalbiai

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2025-03-31 09:31; UTC

Karštos akcijos

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Akcijų palyginimas

Kainos pokytis

AstraZeneca PLC ADR Prognozė

Kainos tikslas

By TipRanks

20.44% į viršų

12 mėnesių prognozė

Vidutinis 87.14 USD  20.44%

Aukščiausias 97 USD

Žemiausias 75 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AstraZeneca PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 69.55Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.